To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
+ND Capital exits CellPoint, via sale to Belgian biotech company Galapagos
“This deal is further validation of our strategy to invest in company creation in Europe," said Patrick Aebischer, Senior Partner at +ND Capital.
